Zui Tan
State Key Laboratory Of Biotherapy
Chengdu, 610041, China
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Design, synthesis, and biological evaluation of a potent and orally bioavailable FGFRs inhibitor for fibrotic treatment.
Journal: European journal of medicinal chemistry
Published: October 25, 2024
Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis.
Journal: European journal of medicinal chemistry
Published: August 09, 2022
Niclosamide-loaded nanoparticles (Ncl-NPs) reverse pulmonary fibrosis in vivo and in vitro.
Journal: Journal of advanced research
Published: July 21, 2022
An oral phenylacrylic acid derivative suppressed hepatic stellate cell activation and ameliorated liver fibrosis by blocking TGF-β1 signalling.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 30, 2022
Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents.
Journal: European journal of medicinal chemistry
Published: April 21, 2022
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.
Journal: Frontiers in cell and developmental biology
Published: June 25, 2021
Nifuroxazide ameliorates pulmonary fibrosis by blocking myofibroblast genesis: a drug repurposing study.
Journal: Respiratory research
Published: May 24, 2021
A novel multikinase inhibitor SKLB-YTH-60 ameliorates inflammation and fibrosis in bleomycin-induced lung fibrosis mouse models.
Journal: Cell proliferation
Published: October 12, 2020
Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis.
Journal: Phytotherapy research : PTR
Published: December 30, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026